Ernexa Therapeutics (ERNAW) Receivables - Doubtful (2012 - 2018)

Ernexa Therapeutics has reported Receivables - Doubtful for 6 years, with the latest figure at $361000.0 in Q3 2018.

• For the quarter ending Q3 2018, Receivables - Doubtful changed N/A year-over-year to $361000.0; the trailing twelve-month figure through Sep 2018 stood at $361000.0 (changed N/A YoY), and the FY2017 full-year result was $463000.0, up 23.14% from the prior year.
• Receivables - Doubtful for Q3 2018 stood at $361000.0, down from $463000.0 in the prior quarter.
• The five-year high for Receivables - Doubtful was $463000.0 in Q4 2017, with the low at $300000.0 in Q2 2014.
• Historically, Receivables - Doubtful has averaged $375000.0 across 4 years, with a median of $368500.0 in 2016.
• The largest YoY upside for Receivables - Doubtful was 23.14% in 2017 against a maximum downside of 23.14% in 2017.
• Ernexa Therapeutics' Receivables - Doubtful stood at $300000.0 in 2014, then grew by 25.33% to $376000.0 in 2016, then increased by 23.14% to $463000.0 in 2017, then decreased by 22.03% to $361000.0 in 2018.
• The last three Receivables - Doubtful figures came in at $361000.0 (Q3 2018), $463000.0 (Q4 2017), and $376000.0 (Q4 2016), per Business Quant data.